Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians

Clinical and Translational Science

Volumn 9, Issue 1, 2016, Pages 36-42

  Hamadeh, Is ^a   Shahin, Mh ^a   Lima, Sm ^a   Oliveira, F ^a   Wilson, L ^a,b   Khalifa, Si ^c   Langaee, Ty ^a   Cooper Dehoff, Rm ^a   Cavallari, Lh ^a   Johnson, Ja ^a,d  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b FLORIDA A AND M UNIVERSITY   (United States)

^c Qatar University ^*  (Qatar)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; GUANINE; PROTEIN STX1B; PROTEIN VKORC1; TETRAHYDROFOLATE SYNTHASE; UNCLASSIFIED DRUG; VITAMIN K DEPENDENT CARBOXYLASE; VITAMIN K EPOXIDE REDUCTASE; WARFARIN; GLUTAMYL CARBOXYLASE; LIGASE; MICROSATELLITE DNA; PEPTIDE SYNTHASE; STX1B PROTEIN, HUMAN; SYNTAXIN 1;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; EGYPTIAN; EUROPEAN AMERICAN; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VENOUS THROMBOEMBOLISM; CAUCASIAN; EGYPT; FEMALE; GENETICS; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

ADULT; AGED; CARBON-CARBON LIGASES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EGYPT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; PEPTIDE SYNTHASES; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; SYNTAXIN 1; WARFARIN;

EID: 84958683250     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12385     Document Type: Article

References (42)

1. Willey, V.J. et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin. Ther. 26, 1149-1159 (2004).
2. Palareti, G. et al. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb. Haemost. 78, 1438-1443 (1997).
3. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N. Engl. J. Med. 333, 5-10 (1995).
4. van der Meer, F.J., Rosendaal, F.R., Vandenbroucke, J.P. & Briet, E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch. Intern. Med. 153, 1557-1562 (1993).
5. Wadelius, M. & Pirmohamed, M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 7, 99-111 (2007).
6. Gage, B.F. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331 (2008).
7. Klein, T.E. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
8. Wadelius, M. et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113, 784-792 (2009).
9. Finkelman, B.S., Gage, B.F., Johnson, J.A., Brensinger, C.M. & Kimmel, S.E. Genetic warfarin dosing: tables versus algorithms. J. Am. Coll. Cardiol. 57, 612-618 (2011).
10. Rost, S. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541 (2004).
11. Li, T. et al. Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544 (2004).
12. Wajih, N., Hutson, S.M., Owen, J. & Wallin, R. Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2, 3-epoxide-reducing enzyme of the vitamin K cycle. J. Biol. Chem. 280, 31603-31607 (2005).
13. Choonara, I.A., Haynes, B.P., Cholerton, S., Breckenridge, A.M., Park, B.K. Enantiomers of warfarin and vitamin K1 metabolism. Br. J. Clin. Pharmacol. 22, 729-732 (1986).
14. Rettie, A.E. et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992).
15. Yamazaki, H. & Shimada, T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem. Pharmacol. 54, 1195-1203 (1997).
16. Kaminsky, L.S. & Zhang, Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67-74 (1997).
17. Limdi, N.A. et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9, 511-526 (2008).
18. Schelleman, H. et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin. Pharmacol. Ther. 84, 332-339 (2008).
19. Shikata, E. et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103, 2630-2635 (2004).
20. Liu, Y. et al. Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin. Pharmacol. Ther. 91, 660-665 (2012).
21. Cavallari, L.H. et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87, 459-464 (2010).
22. Cha, P.C. et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum. Mol. Genet. 19, 4735-4744 (2010).
23. Perera, M.A. et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382, 790-796 (2013).
24. Scott, S.A. et al. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 10, 1243-1255 (2009).
25. Blaisdell, J. et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14, 527-537 (2004).
26. Dickmann, L.J. et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol. 60, 382-387 (2001).
27. Schadt, E.E. et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6, e107 (2008).
28. Zhang, X., Li, L., Ding, X. & Kaminsky, L.S. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab. Dispos. 39, 1433-1439 (2011).
29. Hernandez W, G.E. et al. Novel regulatory variant for VKORC1 identified: associations with warfarin dose response and gene expression in African Americans. [Under review]. (2015).
30. Aquilante, C.L. et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79, 291-302 (2006).
31. Shahin, M.H. et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics 21, 130-135 (2011).
32. Andrisin, T.E., Humma, L.M. & Johnson, J.A. Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy 22, 954-960 (2002).
33. Langaee, T. & Ronaghi, M. Genetic variation analyses by Pyrosequencing. Mutat. Res. 573, 96-102 (2005).
34. Gabriel, S.B. et al. The structure of haplotype blocks in the human genome. Science 296, 2225-2229 (2002).
35. Cavallari, L.H. et al. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet. Genomics 22, 152-158 (2012).
36. Henn, B.M. et al. Genomic ancestry of North Africans supports back-to-Africa migrations. PLoS Genet. 8, e1002397 (2012).
37. Wadelius, M. et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
38. Rieder, M.J., Reiner, A.P. & Rettie, A.E. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J. Thromb. Haemost. 5, 2227-2234 (2007).
39. King, C.R. et al. Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb. Haemost. 104, 750-754 (2010).
40. Chen, L.Y. et al. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood 106, 3673-3674 (2005).
41. Daneshjou, R. et al. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood 124, 2298-2305 (2014).
42. Caldwell, M.D. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008).